HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: dc07-1183v1 31/6/1112    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Ashwell, S. G. Articles by Home, P. D. PubMed PubMed Citation Articles by Ashwell, S. G. Articles by Home, P. D. Social Bookmarking                What's this?

Treatment Satisfaction and Quality of Life With Insulin Glargine Plus Insulin Lispro Compared With NPH Insulin Plus Unmodified Human Insulin in Individuals With Type 1 Diabetes

¹ Newcastle University, Newcastle upon Tyne, U.K
² Royal Holloway, University of London, London, U.K
³ sanofi-aventis, Bridgewater, New Jersey
⁴ Health Outcomes Research, Accovion, Frankfurt, Germany

Corresponding author: Dr. Simon G. Ashwell, Diabetes Care Centre, James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, U.K. E-mail: simon.ashwell{at}stees.nhs.uk

OBJECTIVE—The purpose of this study was to compare quality of life (QoL) and treatment satisfaction using insulin glargine plus insulin lispro with that using NPH insulin plus unmodified human insulin in adults with type 1 diabetes managed with multiple injection regimens.

RESEARCH DESIGN AND METHODS—As part of a 32-week, five-center, two-way crossover study in 56 individuals with type 1 diabetes randomized to evening insulin glargine plus mealtime insulin lispro or to NPH insulin (once or twice daily) plus mealtime unmodified human insulin, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Audit of Diabetes Dependent Quality of Life questionnaire were completed at baseline and at weeks 16 and 32, with additional interim DTSQ measurements.

RESULTS—For all patients combined, the mean baseline present QoL score was 1.3, reflecting "good" QoL. Present QoL improved with glargine + lispro but did not change with NPH + human insulin (1.6 ± 0.1 [mean ± SEM] vs. 1.3 ± 0.1, difference 0.3 [95% CI 0.1–0.6]; P = 0.014). Baseline mean average weighted impact score (AWI) of diabetes on QoL was –1.8, indicating a negative impact of diabetes on QoL. The AWI score at end point improved significantly with glargine + lispro but changed little with NPH + human insulin (–1.4 ± 0.1 vs. –1.7 ± 0.1, 0.3 [0.0–0.6]; P = 0.033). Treatment satisfaction (DTSQ 36-0 scale score) at end point was markedly greater with glargine plus lispro compared with that for NPH plus human insulin (32.2 ± 3.4 vs. 23.9 ± 7.2, 8.6 [6.5–10.6]; P < 0.001).

CONCLUSIONS—Insulin glargine plus insulin lispro improves treatment satisfaction, reduces the negative impact of diabetes on QoL, and improves QoL in comparison with NPH insulin plus unmodified human insulin in type 1 diabetes.

Abbreviations: ADDQoL, Audit of Diabetes Dependent Quality of Life • AWI, average weighted impact • DAFNE, Dose Adjustment For Normal Eating • DTSQ, Diabetes Treatment Satisfaction Questionnaire • DTSQc, DTSQ change version • DTSQs, DTSQ status version • ITT, intention-to-treat • QoL, quality of life

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?